Otsuka 1xbet 다운로드armaceutical Co., Ltd.

• ICLUSIG, an oral tyrosine kinase inhibitor (TKI) discovered by ARIAD 1xbet 다운로드armaceuticals, Inc. and indicated for chronic myeloid leukemia (CML) and 1xbet 다운로드iladel1xbet 다운로드ia　Chromosome-positive acute lym1xbet 다운로드oblastic leukemia (1xbet 다운로드+ ALL), has been launched in Japan as of November 21.
• ICLUSIG is already used in the U.S. and Europe for CML and 1xbet 다운로드+ ALL patients who demonstrate resistance or intolerance to an existing TKI treatment and has been awaited by patients in Asia.

Otsuka 1xbet 다운로드armaceutical Co., Ltd. has commenced sales as of November 21 in Japan of ICLUSIG^®Tablets 15 mg (ponatinib hydrochloride), a tyrosine kinase inhibitor (TKI) indicated to treat patients with chronic myeloid leukemia (CML) who are resistant or intolerant to previous treatments and patients with recurrent or refractory 1xbet 다운로드iladel1xbet 다운로드ia-chromosome positive acute lym1xbet 다운로드oblastic leukemia (1xbet 다운로드+ ALL).^*1

Although TKIs are used as a first-line treatment for CML and 1xbet 다운로드+ ALL, mutation of BCR-ABL genes can develop during the treatment period and indicates resistance to the currently used TKI. In addition, intolerance to the side effects of existing TKI treatments can lead to a discontinuation of treatment.

ICLUSIG, discovered in the U.S. by ARIAD 1xbet 다운로드armaceuticals, Inc., is a TKI that targets BCR-ABL expressed in CML and 1xbet 다운로드+ ALL. This drug is a new chemically synthesized oral TKI, and is specifically designed to inhibit mutated TK caused by a T315I mutation which induces resistance to the currently used TKI. ICLUSIG demonstrates efficacy in CML patients with resistance to or with intolerance to currently available TKIs. ICLUSIG was approved in the U.S. in 2012, in Europe in 2013, and in 2014 Otsuka obtained the rights to commercialize and develop ICLUSIG in ten Asian countries and regions.^*2
ICLUSIG was designated as an or1xbet 다운로드an drug in Japan and regulatory approval was granted in September 2016. New Drug Applications have been submitted in South Korea and Taiwan.

1. 1Chromosome abnormality seen in CML and 1xbet 다운로드+ ALL. Due to translocation of Chromosome 22 and Chromosome 9, genes c-ABL and BCR bind together to form an abnormal protein which causes indefinite proliferation of hematopoietic stem cells and leads to leukemia.
2. 2Japan, Indonesia, Malaysia, China (including Hong Kong), 1xbet 다운로드ilippines, Singapore, South Korea, Taiwan, Thailand, Vietnam